Edition:
United States

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

7.92EUR
11:35am EST
Change (% chg)

€0.25 (+3.19%)
Prev Close
€7.68
Open
€7.64
Day's High
€8.02
Day's Low
€7.64
Volume
171,100
Avg. Vol
336,450
52-wk High
€9.44
52-wk Low
€4.41

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €509.78
Shares Outstanding(Mil.): 63.88
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -0.74 -- --
ROI: -25.05 0.60 13.80
ROE: -52.82 -2.18 15.29

BRIEF-Innate Pharma Announces Updated Results On IPH4102

* ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME

Dec 04 2018

AstraZeneca digs deeper into cancer with Innate stake

LONDON/PARIS AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

Oct 23 2018

UPDATE 2-AstraZeneca digs deeper into cancer with Innate stake

* Innate shares jump 29 percent (Updates with executive interviews, latest shares)

Oct 23 2018

French and Benelux stocks-Factors to watch on Oct 23

Oct 23 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

Oct 23 2018

AstraZeneca to buy 9.8 pct stake in France's Innate Pharma

PARIS, Oct 23 British drugmaker AstraZeneca will buy a newly-issued equity stake of 9.8 percent in smaller French peer Innate Pharma, strengthening its presence in the field of immuno-oncology.

Oct 23 2018

BRIEF-Innate Pharma: Phase II Results From Monalizumab/Cetuximab In Head And Neck Cancer

* INNATE PHARMA ANNOUNCED ON SATURDAY PHASE II RESULTS FROM MONALIZUMAB/CETUXIMAB IN HEAD AND NECK CANCER

Oct 22 2018

BRIEF-Innate Pharma Publishes Phase 1 IPH4102 Results

* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA

Oct 01 2018

Earnings vs. Estimates